The estimated Net Worth of Irina Konstantinovsky is at least $13.4 Milione dollars as of 22 February 2021. Ms. Konstantinovsky owns over 5,698 units of Horizon Therapeutics Plc stock worth over $9,499,035 and over the last 7 years she sold HZNP stock worth over $3,658,821. In addition, she makes $219,458 as Chief Human Resource Officer e Executive Vice President at Horizon Therapeutics Plc.
Sign up
Ms. Konstantinovsky HZNP stock SEC Form 4 insiders trading
Irina has made over 9 trades of the Horizon Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 5,698 units of HZNP stock worth $496,980 on 22 February 2021.
The largest trade she's ever made was exercising 59,794 units of Horizon Therapeutics Plc stock on 6 May 2020 worth over $840,106. On average, Irina trades about 12,451 units every 29 days since 2017. As of 22 February 2021 she still owns at least 81,677 units of Horizon Therapeutics Plc stock.
You can see the complete history of Ms. Konstantinovsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Irina Konstantinovsky biography
Irina P. Konstantinovsky is Chief Human Resource Officer, Executive Vice President of the Company. Prior to Horizon, from August 2012 to September 2017, she was vice president of global talent at Baxter International Inc., a healthcare products company, where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide. Prior to Baxter, Ms. Konstantinovsky spent 15 years in senior partner and director roles at Towers Watson (currently Willis Towers Watson), a global human-resources consulting firm serving Fortune 1000 companies. Ms. Konstantinovsky has a bachelor of arts in education from the University of Buenos Aires and two master’s degrees, one in higher education and one in industrial and labor relations from Cornell University.
What is the salary of Irina Konstantinovsky?
As the Chief Human Resource Officer e Executive Vice President of Horizon Therapeutics Plc, the total compensation of Irina Konstantinovsky at Horizon Therapeutics Plc is $219,458. There are 15 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.
How old is Irina Konstantinovsky?
Irina Konstantinovsky is 50, she's been the Chief Human Resource Officer e Executive Vice President of Horizon Therapeutics Plc since 2017. There are 16 older and 7 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
What's Irina Konstantinovsky's mailing address?
Irina's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN, L2, 4.
Insiders trading at Horizon Therapeutics Plc
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... e Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
What does Horizon Therapeutics Plc do?
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
What does Horizon Therapeutics Plc's logo look like?
Complete history of Ms. Konstantinovsky stock trades at Horizon Therapeutics Plc
Horizon Therapeutics Plc executives and stock owners
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Timothy Walbert,
Chairman of the Board, President, Chief Executive Officer -
Timothy P. Walbert,
Chairman, Pres & CEO -
Barry Moze,
Executive Vice President, Chief Administrative Officer -
Paul Hoelscher,
Chief Financial Officer, Executive Vice President -
Vikram Karnani,
Executive Vice President, President - International -
Paul W. Hoelscher,
Exec. VP & CFO -
Andy Pasternak,
Exec. VP & Chief Strategy Officer -
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
Exec. VP & Chief Medical Officer -
Michael Grey,
Lead Independent Director -
Jeffrey Himawan,
Independent Director -
H. Thomas Watkins,
Independent Director -
James Shannon,
Independent Director -
William Daniel,
Independent Director -
Pascale Witz,
Independent Director -
Susan Mahony,
Independent Director -
Irina Konstantinovsky,
Chief Human Resource Officer, Executive Vice President -
Daniel Camardo,
Executive Vice President, President - U.S. -
Jeffrey Kent,
Senior Vice President, Head of Medical Affairs and Outcomes Research -
Andy Pasternak,
Executive Vice President, Chief Business Officer -
Geoffrey Curtis,
Executive Vice President - Corporate Affairs, Chief Communications Officer -
Tina Ventura,
Senior Vice President, Investor Relations -
Michael DesJardin,
Executive Vice President - Technical Operations and Corporate Quality -
Brian Beeler,
Executive Vice President, General Counsel -
Aaron L. Cox,
Exec. VP of Fin. & CFO -
Jane Gonnerman,
Group VP of Corp. Devel., Chief of Staff & Office of the CEO -
Geoffrey M. Curtis,
Exec. VP of Corp. Affairs & Chief Communications Officer -
Sean M. Clayton J.D.,
Exec. VP & Gen. Counsel -
Timothy Ayers,
Chief Compliance Officer & VP -
Dr. Karin Rosen M.D., Ph.D.,
Exec. VP of R&D and Chief Scientific Officer -
Miles W. McHugh,
Chief Accounting Officer & Sr. VP -
Robert Carey,
EVP & Chief Business Officer -
Jeff Himawan,
Director -
Gino Santini,
Director -
Timothy J. Ackerman,
SVP, Commercial Operations -
Miles W Mc Hugh,
Sr VP & Princ. Acctg Officer -
George P Hampton,
See remarks -
Virinder Nohria,
Director -
Ronald Pauli,
Director -
Vaere Robert J De,
EVP & CFO -
Therapeutics Holdings Llc V...,
10% owner -
Todd N Smith,
SVP, Marketing & Alliance Mgmt -
David Happel,
EVP, Commercial Dev & Strategy -
Eric Mosbrooker,
SVP, Orphan Business Unit -
Shao Lee Lin,
EVP, Head of R&D and CSO -
Jeff Kent,
See remarks -
Jeffrey W Bird,
Director -
Michael Adatto,
Senior VP Sales & Managed Care -
Bio Ventures Ii Lp Quaker,
10% owner -
Venture Fund Vi Lp Atlas Ve...,
-
Peter Johann,
Director -
Jean Francois Formela,
Director -
Venture Fund Vi Lp Atlas Ve...,
-
Woodlands Health Ventures F...,
10% owner -
Louis C Bock,
Director -
Hubert Birner,
Director -
John B Thomas,
EVP, Corporate Strategy and IR -
David George Kelly,
EVP, Company Secretary -
John J Kody,
EVP, Chief Commercial Officer -
Balaji Venkataraman,
-
Aaron Cox,
EVP, Chief Financial Officer -
Jeffrey W Sherman,
EVP and Chief Medical Officer -
Karin Rosen,
EVP, R&D & CSO -
Elizabeth H.Z. Thompson,
EVP, Research & Development -
Sean M. Clayton,
EVP, General Counsel -
Jacopo Leonardi,
Pres., Global Commercial Ops -
Patrick Mc Ilvenny,
Chief Accounting Officer